MedAdvisor
Market Cap
AU$125.8m
Last Updated
2021/01/15 07:04 UTC
Data Sources
Company Financials
Executive Summary
MedAdvisor Limited, together with its subsidiaries, develops and delivers software for personal medication management in Australia. More Details
Risk Analysis
Snowflake Analysis
Flawless balance sheet and overvalued.
Share Price & News
How has MedAdvisor's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MDR is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: MDR's weekly volatility has decreased from 15% to 7% over the past year.
Market Performance
7 Day Return
-1.4%
MDR
7.9%
AU Healthcare Services
0.1%
AU Market
1 Year Return
-33.0%
MDR
18.3%
AU Healthcare Services
-1.6%
AU Market
Return vs Industry: MDR underperformed the Australian Healthcare Services industry which returned 18.3% over the past year.
Return vs Market: MDR underperformed the Australian Market which returned -1.6% over the past year.
Shareholder returns
| MDR | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.4% | 7.9% | 0.1% |
| 30 Day | -1.4% | 13.6% | 2.3% |
| 90 Day | -9.0% | 16.8% | 9.8% |
| 1 Year | -32.0%-33.0% | 18.9%18.3% | 1.7%-1.6% |
| 3 Year | 2.9%1.4% | 137.6%127.5% | 25.7%10.1% |
| 5 Year | 39.1%37.1% | 257.7%250.6% | 70.7%37.2% |
Long-Term Price Volatility Vs. Market
How volatile is MedAdvisor's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares4 weeks ago | Simply Wall St
What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?1 month ago | Simply Wall St
Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn SituationValuation
Is MedAdvisor undervalued compared to its fair value and its price relative to the market?
5.26x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MDR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MDR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MDR is unprofitable, so we can't compare its PE Ratio to the XX Healthcare Services industry average.
PE vs Market: MDR is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MDR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MDR is good value based on its PB Ratio (5.3x) compared to the AU Healthcare Services industry average (5.5x).
Next Steps
Future Growth
How is MedAdvisor forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
35.1%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MedAdvisor has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine MedAdvisor's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- MedAdvisor competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has MedAdvisor performed over the past 5 years?
-35.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDR is currently unprofitable.
Growing Profit Margin: MDR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDR is unprofitable, and losses have increased over the past 5 years at a rate of 35.9% per year.
Accelerating Growth: Unable to compare MDR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-8.6%).
Return on Equity
High ROE: MDR has a negative Return on Equity (-57.46%), as it is currently unprofitable.
Next Steps
Financial Health
How is MedAdvisor's financial position?
Financial Position Analysis
Short Term Liabilities: MDR's short term assets (A$14.6M) exceed its short term liabilities (A$3.0M).
Long Term Liabilities: MDR's short term assets (A$14.6M) exceed its long term liabilities (A$1.2M).
Debt to Equity History and Analysis
Debt Level: MDR is debt free.
Reducing Debt: MDR has no debt compared to 5 years ago when its debt to equity ratio was 267.5%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MDR has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 31.2% each year.
Next Steps
Dividend
What is MedAdvisor current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MDR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MDR's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.9yrs
Average management tenure
CEO
Robert Read
5.17yrs
Tenure
AU$461,073
Compensation
Mr. Robert Read, BComm(Mgt), BA(Psych), GAICD., has been the Chief Executive Officer of MedAdvisor Limited since November 12, 2015 and also serves as its Managing Director. Mr. Read served as Managing Dire...
CEO Compensation Analysis
Compensation vs Market: Robert's total compensation ($USD358.92K) is about average for companies of similar size in the Australian market ($USD295.31K).
Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Executive Director | 5.17yrs | AU$461.07k | 0.81% A$ 1.0m | |
| Founder | 5.17yrs | AU$282.70k | 4.32% A$ 5.4m | |
| Chief Financial Officer | 1.5yrs | AU$264.82k | no data | |
| Company Secretary | 5.08yrs | AU$204.07k | 0.95% A$ 1.2m | |
| Interim Chief Technology Officer | 0.58yr | no data | no data | |
| Company Secretary & General Counsel | 0.42yr | no data | no data | |
| Corporate Communications Manager | no data | no data | no data | |
| Head of Sales & Marketing | 5.08yrs | no data | no data | |
| Executive General Manager of People & Culture | 2.33yrs | no data | no data | |
| Head of Commercial | no data | no data | no data | |
| President & CEO of the US business | no data | no data | no data | |
| Chief Revenue Officer | 1yr | no data | no data |
1.9yrs
Average Tenure
Experienced Management: MDR's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Executive Director | 5.17yrs | AU$461.07k | 0.81% A$ 1.0m | |
| Founder | 5.17yrs | AU$282.70k | 4.32% A$ 5.4m | |
| Non-Executive Director | 1.25yrs | no data | no data | |
| Non-Executive Director | 7.17yrs | AU$75.56k | 0.45% A$ 566.6k | |
| Independent Non-Executive Director | 5yrs | AU$280.20k | 0.070% A$ 87.5k | |
| Non-Executive Chairman of the Board | 0.92yr | AU$44.50k | 0.051% A$ 64.5k | |
| Member of Advisory Board | 4.83yrs | no data | no data | |
| Non-Executive Director | 5.17yrs | AU$49.28k | 5.71% A$ 7.2m | |
| Member of Advisory Board | 4.83yrs | AU$25.89k | no data | |
| Member of Advisory Board | 4.83yrs | no data | no data |
4.9yrs
Average Tenure
Experienced Board: MDR's board of directors are considered experienced (4.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MDR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.2%.
Top Shareholders
Company Information
MedAdvisor Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: MedAdvisor Limited
- Ticker: MDR
- Exchange: ASX
- Founded: 2010
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$125.817m
- Shares outstanding: 359.48m
- Website: https://www.medadvisor.com.au
Location
- MedAdvisor Limited
- 971 Burke Road
- Level 2
- Camberwell
- Victoria
- 3124
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MDR | ASX (Australian Securities Exchange) | Yes | Share Capital | AU | AUD | Dec 2015 |
| MDR | CHIA (Chi-X Australia) | Yes | Share Capital | AU | AUD | Dec 2015 |
Biography
MedAdvisor Limited, together with its subsidiaries, develops and delivers software for personal medication management in Australia. It develops and deploys the MedAdvisor, a medication and adherence platfo...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/15 07:04 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.